The purpose of the trial is to determine whether the experimental drug can lower disease activity compared with a placebo. Adults will be randomly assigned to receive either the study drug or the placebo, and neither the participants nor the study staff will know which treatment is given. Injections will be given at regular intervals over about six months, with clinic visits to assess muscle strength, skin involvement, and any side effects. Researchers will track changes using simple scores that measure overall improvement and skin disease activity, and they will also monitor whether participants can reduce their steroid dose safely.

People taking part in this study must be adults between 18 and 75 years old who have been diagnosed with dermatomyositis and have active muscle and skin disease. Participants should have received or be receiving treatment with corticosteroids, hydroxychloroquine, or other medicines that affect the immune system. The study will measure improvement using a scoring system that looks at different aspects of the disease, including muscle strength, skin condition, overall health as rated by both the doctor and the patient, ability to perform daily activities, and levels of certain enzymes in the blood that indicate muscle damage.

During the study, participants will take their assigned medicine by mouth in tablet form for up to 114 days. The study will track various measures of improvement at different time points, with the main assessment happening at week 52. These measures include changes in skin disease activity scores, the proportion of people who show moderate or major improvement, how quickly improvement occurs, and changes in the ability to carry out daily activities. The study will also look at whether participants can reduce their dose of prednisone or similar corticosteroid medicines while still showing improvement.

Participants in this study will receive dazukibart, which is a type of medication known as a monoclonal antibody. This medication is designed to target and neutralize specific proteins in the body that may contribute to inflammation. The study will also involve other medications, including betamethasone, hydroxychloroquine, chloroquine phosphate, hydrocortisone, triamcinolone acetonide, methylprednisolone, mycophenolate mofetil, budesonide, dexamethasone, azathioprine, prednisolone, methotrexate, deflazacort, leflunomide, and prednisone. Some participants may receive a placebo instead of the active medication.

The study will last for up to 52 weeks, during which participants will be monitored for any side effects and changes in their condition. The goal is to gather information on the safety of dazukibart and its effectiveness in managing symptoms of idiopathic inflammatory myopathies. Participants will undergo regular check-ups and assessments to track their progress and any changes in their health status.

The purpose of the study is to determine if Anifrolumab can provide a moderate improvement in disease activity over a period of 52 weeks. Participants will receive either Anifrolumab or a placebo through subcutaneous injections, which means the medication is injected under the skin. The study will follow a double-blind method, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will continue their usual treatments for Polymyositis or Dermatomyositis, and their progress will be monitored to assess any changes in their condition. The trial aims to provide valuable information on whether Anifrolumab can be a beneficial addition to the current standard of care for these conditions.

Participants in the study will receive either Baricitinib or a placebo, and their progress will be monitored at various intervals, including weeks 4, 8, 12, 16, and 24. The main goal is to see if there is a 20% or greater improvement in the symptoms of Juvenile Dermatomyositis, such as muscle strength and skin condition, without significant worsening of any other symptoms. The study will also look at other levels of improvement and any changes in lung function, if applicable, as well as any side effects experienced by participants.

Throughout the study, various health markers will be measured, including certain proteins in the blood that are related to inflammation and immune response. Additionally, the study will examine the expression of genes related to immunity and assess muscle tissue samples to better understand the effects of Baricitinib. The trial is expected to conclude in June 2026, providing valuable insights into the potential benefits of Baricitinib for children with new-onset Juvenile Dermatomyositis.

Participants in the study will receive either Baricitinib or a placebo in the form of film-coated tablets. The study will last for a period of 24 weeks, during which the participants’ progress will be monitored. The main focus is to observe moderate improvement in the condition without the use of corticosteroids like prednisone. The study will also look at other aspects such as the improvement of muscle strength and skin condition, the occurrence of relapses, and the overall safety of the treatment.

The study aims to provide valuable information on whether Baricitinib can be an effective treatment option for people with Dermatomyositis, potentially reducing the need for steroids and improving the quality of life for those affected by this condition. Participants will be closely monitored throughout the study to ensure their safety and to gather comprehensive data on the treatment’s effects.

The purpose of the study is to assess whether patients can maintain stable disease activity without the need for intravenous immunoglobulins (IVIG), a common treatment for these conditions. Participants in the study will be randomly assigned to receive either Upadacitinib or a placebo, which is a substance with no active medication. The study will last for a period of 20 weeks, during which the participants’ health and disease activity will be closely monitored. The main goal is to see if patients can remain stable without IVIG by the 16th week of the study.

Throughout the trial, various aspects of the participants’ health will be evaluated, including muscle strength, quality of life, and any side effects experienced. The study will also compare the time it takes for symptoms to worsen between those taking Upadacitinib and those taking the placebo. This research aims to provide valuable insights into the potential of Upadacitinib as a treatment option for individuals with idiopathic inflammatory myopathies, potentially reducing the need for IVIG and improving overall management of these conditions.

Participants in the study will receive either Empasiprubart or a placebo. The study is designed to be double-blinded, which means neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The study will take place over a period of up to 90 weeks, with participants being monitored for any adverse events, which are any unwanted effects that might occur during the study. The study will also measure how many participants stop taking the study medication due to these adverse events within the first 25 weeks.

Throughout the study, researchers will also evaluate the improvement in participants’ conditions using a measure called the Total Improvement Score (TIS) at specific intervals, such as weeks 13 and 25. This score helps determine how well the treatment is working in improving the symptoms of Dermatomyositis. The study aims to provide valuable information on the potential benefits and risks of using Empasiprubart as a treatment option for this condition.

The purpose of this study is to evaluate the safety and the relationship between the body’s immune response and the clinical outcomes when using low-dose IL-2 therapy in patients with these diseases. Participants will receive the treatment over a period of eight weeks. The study is designed to be randomized, meaning participants will be randomly assigned to different groups, and double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or a placebo. This helps ensure the results are unbiased.

Throughout the study, researchers will monitor the participants’ immune responses and any changes in their disease symptoms. The goal is to understand how the treatment affects the immune system and whether it leads to improvements in the conditions being studied. The trial will help determine if low-dose IL-2 therapy is a safe and effective option for managing these chronic inflammatory diseases.

The purpose of the study is to evaluate how effective and safe IgPro20 is for adults with dermatomyositis. Participants in the study will receive either the IgPro20 treatment or a placebo. The study will last for several weeks, during which participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to see if the treatment can improve symptoms and overall health in people with dermatomyositis.

Throughout the study, participants will be assessed on their improvement using a scoring system that measures various aspects of their condition, such as muscle strength and skin symptoms. The study will also look at whether participants can reduce their use of other medications, like corticosteroids, which are often used to manage symptoms of dermatomyositis. The results will help determine if IgPro20 is a beneficial treatment option for this condition.

The study will also involve other medications that are commonly used to manage these conditions, such as methotrexate, azathioprine, and various glucocorticosteroids like methylprednisolone, dexamethasone, and prednisone. These medications help reduce inflammation and suppress the immune system. The trial will last for about a year, during which participants will receive regular treatments and assessments to monitor their muscle symptoms and overall health.

The purpose of this study is to determine if PF-06823859 can effectively reduce muscle symptoms in adults with active dermatomyositis or polymyositis. Participants will be randomly assigned to different groups to receive either the study medication or a placebo, and their progress will be closely monitored by healthcare professionals. The study will help researchers understand the potential benefits and risks of this new treatment option for people living with these challenging muscle conditions.

The purpose of this study is to see how filgotinib affects the quality of life, disease activity, and safety in patients who have these conditions and have not responded well to other treatments. Participants in the study will receive either filgotinib or a placebo, and their progress will be monitored over a period of time. The study will look at various aspects of the diseases, such as the number of oral ulcers, skin disease severity, and overall disease activity, to determine how well the treatment is working.

Throughout the study, participants will be asked to complete forms and assessments to help researchers understand the impact of the treatment on their symptoms and daily life. The study aims to provide valuable information on the potential benefits and safety of using filgotinib for these rare immune-mediated inflammatory diseases. The results could lead to improved treatment options for patients with these challenging conditions.

The study will be conducted over a period of 48 weeks. During this time, participants will be randomly assigned to receive either Enpatoran or a placebo. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The main focus will be on the improvement of symptoms and the safety of the treatment.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition. These check-ups will include assessments of muscle strength and skin condition, as well as routine laboratory tests to ensure the safety of the treatment. The study aims to provide valuable information on whether Enpatoran can be a beneficial treatment option for those living with Dermatomyositis and Polymyositis.

The purpose of the study is to evaluate the effectiveness and safety of GLPG3667 over a period of 24 weeks. Participants will be randomly assigned to receive either the GLPG3667 capsule or a placebo. Throughout the study, participants will have regular check-ups to monitor their health and any changes in their symptoms. The study aims to determine if GLPG3667 can provide at least minimal improvement in the condition by the end of the 24 weeks.

In addition to assessing the improvement in symptoms, the study will also look at the safety and tolerability of GLPG3667. This includes monitoring any side effects that may occur during the treatment period. Participants who complete the initial 24-week period may have the opportunity to continue receiving GLPG3667 in an open-label extension, where all participants receive the active treatment. This extension will help further evaluate the long-term safety and benefits of the treatment.

The purpose of this study is to examine the safety and effectiveness of filgotinib in patients whose symptoms have not improved with standard treatments. Participants in the study will receive either Jyseleca 100 mg or Jyseleca 200 mg film-coated tablets, which contain the active substance filgotinib. The study will last for a period of up to 26 weeks, during which participants will take the medication orally. Some participants may receive a placebo instead of the active medication. Throughout the study, participants will be monitored to assess how well the medication is working and to check for any side effects.

By participating in this study, researchers hope to gather valuable information about the potential benefits and risks of using filgotinib for treating these rare inflammatory diseases. The findings from this study could help improve treatment options for patients with these conditions in the future.